• La MRD est-elle importante sous ibrutinib ?

    Réf :HematoStat.net ; 2 (7) : V62 Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. Wang XV, Hanson CA, Tschumper RC, Lesnick CE, Braggio […]

    Published On: 12 July 2022

  • Hématopoièse clonale avant immunochimiothérapie ?

    Réf :HematoStat.net ; 2 (4) : V55 Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy. Voso MT, Pandzic T, […]

    Published On: 27 April 2022

  • Un peu de provocation ne fait jamais de mal

    Réf :HematoStat.net ; 1 (11) : V28 Van Gelder M, Tournilhac O, Te Raa D, Visser HPJ. Front-line chemo- immunotherapy is not inferior to ibrutinib in CLL. Ann Oncol. 2021 […]

    Published On: 29 November 2021